BioMarin Pharmaceutical Inc. (BMRN)$54.09
Market Cap: 11.90 BCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for BioMarin Pharmaceutical Inc. (BMRN).
HEALTHCARE
BIOTECHNOLOGY
DCF ready
Valuation
14.6x
EV/FCF, 6.8% FCF yield
Quality
5.7%
ROIC, 22.5% FCF margin
Growth
11.6%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 5.2x current ratio
Superinvestors
3
Top: Viking Global Investors (1.1%)
Strengths to research
- Revenue compounded at 11.6% over five years.
- Free cash flow margin is healthy at 22.5%.
- Debt/equity looks manageable at 0.0x.
- 3 tracked superinvestors report a position.
Watchouts
No major valuation, balance sheet, or growth watchouts were detected by the static screen.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for BMRN.
Grade C
57
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| BMRN Target | BioMarin Pharmaceutical Inc. | $11.9B | 30.1x | 14.6x | 5.7% | 11.6% | 22.5% | N/A | -2.7x | N/A |
| INCY | Incyte Corp. | $12.0B | 15.2x | 6.3x | 24.9% | 14.0% | 27.5% | N/A | -1.9x | N/A |
| MRNA | Moderna, Inc. | $10.8B | -6.5x | -4.0x | -32.6% | 19.3% | -106.2% | N/A | N/A | N/A |
| ROIV | Roivant Sciences Ltd | $8.3B | -55.5x | -9.0x | -6.6% | -19.1% | -9183.5% | N/A | N/A | N/A |
| TECH | Bio-Techne Corp. | $7.9B | 104.8x | 30.1x | 3.8% | 10.5% | 21.0% | 64.8% | -0.8x | N/A |
| HALO | Halozyme Therapeutics | $7.5B | 26.7x | 14.7x | 14.5% | 39.2% | 46.2% | N/A | 4.2x | N/A |
| RPRX | Royalty Pharma plc | $19.0B | 30.6x | 11.0x | 4.1% | 2.3% | 104.7% | N/A | 5.3x | N/A |
| BBIO | BridgeBio Pharma Inc. | $7.3B | -18.3x | -19.5x | N/A | 127.4% | -89.0% | N/A | N/A | N/A |
| LEGN | Legend Biotech Corp. | $6.1B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Financial Charts
No financial data available for BMRN (annual).
3 superinvestors own BMRN
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Dodge & Cox Dodge & Cox | 14,561,759 | $823M | 0.45% | 0.0% |
| Viking Global Investors Viking Global Investors | 7,062,077 | $399M | 1.12% | 0.0% |
| Torray Funds Torray Funds | 78,170 | $4M | 0.69% | 0.0% |